Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Merck & Co., Inc
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 5 ans
Pembrolizumab or placebo in combination with chemoradiation (CRT) in subjects with locally advanced HNSCC
To compare Event-free survival (EFS) per RECIST (Response Evaluation Criteria in Solid Tumors) 1.1 by blinded independent central review (BICR) in subjects treated with pembrolizumab in combination wi...
Country
None
organs
None
Specialty
None
unknown
More information
Woman Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 5 ans
A Six Month Phase II/III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerabitlity, and Efficacy of Telcagepant (MK-0974) for prevention of Menstrually Related Migraine in Female Patients with Episodic Migraine
1. To evaluate the efficacy of telcagepant 140 mg once daily for 7-days per month compared to placebo for the prevention of migraine during the study period in female patients with menstruelly relate...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck & Co., Inc
Update Il y a 5 ans
An Open Label, Randomized Phase I/IIa Trial Evaluating MK-0646 in Combination With Erlotinib (TARCEVA™) for Patients With Recurrent Non-Small Cell Lung Cancer
Phase I: To determine the safety and tolerability of erlotinib in combination with MK-0646 in patients with recurrent NSCLC. Phase II: To evaluate the effect of the combination of erlotinib and MK-064...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 5 ans
Pediatric study to evaluate the appropriate dose for aprepitant in pediatric patients undergoing surgery. Estudio pediatrico para evaluar la dosis apropiada de aprepitant en pacientes pediátricos para la prevención de las náuseas y los vómitos postoperatorios
To estimate post-operative aprepitant plasma concentration profiles and pharmacokinetic parameters by population analysis including historical data (e.g. Cmax, Tmax, AUC0-?, t1/2, CL/F) in Dose 1, 2, ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck & Co., Inc
Update Il y a 5 ans
Assessment of Safety and Single-Dose Pharmacokinetics in Children
To assess the safety and tolerability of single doses of rizatriptan ODT in pediatric migraineurs ages 6 - 17 years. To obtain preliminary plasma pharmacokinetic data (e.g., AUC, Cmax, Tmax, and termi...
Country
None
organs
None
Specialty
None
More information
Woman and Man Max 99 years
Merck & Co., Inc
Update Il y a 5 ans
A Phase III Randomized, Active-Comparator (Pioglitazone) Controlled Clinical Trial to Study the Efficacy and Safety of MK-0431A (A Fixed-Dose Combination Tablet of Sitagliptin and Metformin) in Patients With Type 2 Diabetes Mellitus
HbA1c after 32 weeks; safety and tolerability
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 5 ans
Trial 1 to Assess MK-8342B Treatment Efficacy-Safety in Dysmenorrhea plus Extension
1) Objective: To evaluate the efficacy of the ENG-E2 vaginal ring relative to placebo in the treatment of dysmenorrhea at Treatment Cycle 2. 2) Objective: To assess the safety and tolerability of the...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman Max 99 years
Merck & Co., Inc
Update Il y a 5 ans
A Randomized, International, Double-Blinded (With In-House Blinding), Controlled With GARDASIL™, Tolerability, Immunogenicity, and Efficacy Study of a Second Generation Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered to 16- to 26-Year-Old Women
To evaluate the tolerability of the octavalent HPV L1 VLP vaccine when administered to 16- to 26-year-old women. To demonstrate that administration of octavalent HPV L1 VLP vaccine will reduce the c...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 5 ans
Pembrolizumab vs Chemotherapy in Microsatellite Instability-High or Mismatch Repair Deficient Stage IV Colorectal Cancer
To compare Progression Free Survival (PFS) per RECIST 1.1 by central imaging vendor in subjects with first line (1L) stage IV MSI-H or dMMR CRC treated with pembrolizumab versus SOC chemotherapies.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 5 ans
A Phase 3 study in Patients with Type 2 Diabetes Mellitus
To assess the impact of MK-3102 25 mg q.w. on time to confirmed CV outcomes as measured by the time to first event in the CV composite endpoint of CV-related death, nonfatal MI, nonfatal stroke, or un...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
11
12
13
14
15
16
17
18
19
20
Next